Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry
in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of …

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, developing effective therapies to …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Neurofibrillary tangles, one of the neuropathologic hallmarks of Alzheimer's disease, have a
dynamic lifespan of maturity that associates with progressive neuronal dysfunction and …

Alzheimer's Disease (AD) contributes to most cases of dementia. Its prominent
neuropathological features are the extracellular neuritic plaques and intercellular …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …